DK3296407T3 - Mutationer i PIK3CA-genet ved humane cancerformer - Google Patents

Mutationer i PIK3CA-genet ved humane cancerformer Download PDF

Info

Publication number
DK3296407T3
DK3296407T3 DK17197306.8T DK17197306T DK3296407T3 DK 3296407 T3 DK3296407 T3 DK 3296407T3 DK 17197306 T DK17197306 T DK 17197306T DK 3296407 T3 DK3296407 T3 DK 3296407T3
Authority
DK
Denmark
Prior art keywords
mutations
human cancers
pik3ca gene
pik3ca
gene
Prior art date
Application number
DK17197306.8T
Other languages
English (en)
Inventor
Yardena Samuels
Victor Velculescu
Kenneth Kinzler
Bert Vogelstein
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3296407(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK3296407T3 publication Critical patent/DK3296407T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
DK17197306.8T 2004-03-02 2005-02-18 Mutationer i PIK3CA-genet ved humane cancerformer DK3296407T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54888604P 2004-03-02 2004-03-02
EP15150891.8A EP2896703B1 (en) 2004-03-02 2005-02-18 Mutations of the PIK3CA gene in human cancers

Publications (1)

Publication Number Publication Date
DK3296407T3 true DK3296407T3 (da) 2019-08-19

Family

ID=35056655

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17197306.8T DK3296407T3 (da) 2004-03-02 2005-02-18 Mutationer i PIK3CA-genet ved humane cancerformer
DK19175606.3T DK3556866T3 (da) 2004-03-02 2005-02-18 Mutationer af pik3ca-genet i humane cancere
DK05723277.9T DK1730303T3 (da) 2004-03-02 2005-02-18 Mutationer i pik3ca-genet ved humane cancerformer

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK19175606.3T DK3556866T3 (da) 2004-03-02 2005-02-18 Mutationer af pik3ca-genet i humane cancere
DK05723277.9T DK1730303T3 (da) 2004-03-02 2005-02-18 Mutationer i pik3ca-genet ved humane cancerformer

Country Status (14)

Country Link
US (6) US8026053B2 (da)
EP (5) EP2497836B1 (da)
JP (10) JP2007530017A (da)
AU (2) AU2005227148B2 (da)
CA (1) CA2560696C (da)
CY (1) CY1121975T1 (da)
DK (3) DK3296407T3 (da)
ES (5) ES2663248T3 (da)
HU (1) HUE045690T2 (da)
LT (1) LT3296407T (da)
PL (2) PL1730303T3 (da)
PT (3) PT3296407T (da)
SI (2) SI1730303T1 (da)
WO (1) WO2005091849A2 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2663248T3 (es) 2004-03-02 2018-04-11 The Johns Hopkins University Mutaciones del gen de PIK3CA en cánceres humanos
EP1849877A1 (en) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Replicative history of T-and B-cell subsets
WO2008109375A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
JP2011505124A (ja) 2007-12-03 2011-02-24 エンゾン ファーマシューティカルズ，インコーポレーテッド Ｐｉｋ３ｃａ発現をモジュレーションするためのｒｎａアンタゴニスト化合物
WO2009152346A2 (en) * 2008-06-11 2009-12-17 Intradigm Corporation Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
WO2011119934A2 (en) 2010-03-26 2011-09-29 Mayo Foundation For Medical Education And Research Methods and materials for detecting colorectal neoplasm
AU2011329180A1 (en) * 2010-11-15 2013-05-02 Enzon Pharmaceuticals, Inc. Methods of treating cancers with HER3 and PIK3CA antisense oligonucleotides
JP2013545756A (ja) * 2010-11-16 2013-12-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 投与および治療方法
WO2012106175A1 (en) 2011-02-02 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
EP3246416A1 (en) 2011-04-15 2017-11-22 The Johns Hopkins University Safe sequencing system
CN104010494B (zh) * 2011-07-28 2017-07-04 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
CN102816839A (zh) * 2012-07-06 2012-12-12 杭州艾迪康医学检验中心有限公司 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒
EP2912468B1 (en) 2012-10-29 2018-09-12 The Johns Hopkins University Papanicolaou test for ovarian and endometrial cancers
CN108130373A (zh) * 2013-03-13 2018-06-08 豪夫迈·罗氏有限公司 在人pi3kca (pik3ca)基因中检测突变的方法和组合物
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
KR101501826B1 (ko) * 2013-04-05 2015-03-13 연세대학교 산학협력단 위암에 대한 예후 예측 모형의 제조방법
WO2015017528A1 (en) * 2013-07-30 2015-02-05 Blueprint Medicines Corporation Pik3c2g fusions
EP3126519A4 (en) 2014-03-31 2018-01-17 Mayo Foundation for Medical Education and Research Detecting colorectal neoplasm
LT3198026T (lt) * 2014-08-07 2020-01-27 Pharmassist Ltd Pik3ca mutacijos statuso nustatymo mėginyje būdas
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
US10435755B2 (en) 2015-03-27 2019-10-08 Exact Sciences Development Company, Llc Detecting esophageal disorders
CN107949642B (zh) * 2015-05-27 2022-04-26 奎斯特诊断投资股份有限公司 用于筛选实体瘤的组合物和方法
WO2017027653A1 (en) 2015-08-11 2017-02-16 The Johns Hopkins University Assaying ovarian cyst fluid
AU2016315924B2 (en) 2015-08-31 2022-08-25 Exact Sciences Corporation Detecting gastric neoplasm
RU2018123524A (ru) 2015-12-03 2020-01-09 Новартис Аг Фармацевтическая диагностика
RU2608960C1 (ru) * 2016-03-18 2017-01-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Клеточная линия crov Cel муцинозного рака яичников человека, предназначенная для разработки лечения таргетными препаратами
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
WO2017180886A1 (en) 2016-04-14 2017-10-19 Mayo Foundation For Medical Education And Research Detecting pancreatic high-grade dysplasia
CN110431241B (zh) 2017-02-28 2024-04-19 梅约医学教育与研究基金会 检测前列腺癌
EP3604521A4 (en) * 2017-03-30 2021-05-19 The University of Tokyo METHOD OF EVALUATING SEVERAL DIFFERENT GENES OF INTEREST
JP7067896B2 (ja) 2017-10-27 2022-05-16 シスメックス株式会社 品質評価方法、品質評価装置、プログラム、および記録媒体
US10975443B2 (en) 2017-11-30 2021-04-13 Mayo Foundation For Medical Education And Research Detecting breast cancer
CN111363827A (zh) * 2020-04-30 2020-07-03 北京和合医学诊断技术股份有限公司 用于检测pik3ca基因突变的引物组及其应用方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
CN116219015A (zh) * 2023-02-06 2023-06-06 中日友好医院(中日友好临床医学研究所) 基于pcr的dna中pik3ca基因突变检测试剂盒及检测方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5846824A (en) * 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846624A (en) * 1996-12-06 1998-12-08 The Standard Register Company Dual face pressure sensitive label
US7670767B1 (en) * 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
US6277563B1 (en) 1997-01-16 2001-08-21 The Regents Of The University Of California Genetic alterations associated with cancer
US6558903B1 (en) 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
JP4652648B2 (ja) * 1999-08-27 2011-03-16 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド キメラアンチセンスオリゴヌクレオチド、およびその細胞トランスフェクション処方物
CA2395398A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001294842A1 (en) * 2000-09-28 2002-04-08 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20020142305A1 (en) 2001-03-27 2002-10-03 Koei Chin Methods for diagnosing and monitoring ovarian cancer by screening gene copy numbers
US20030135033A1 (en) * 2002-01-04 2003-07-17 Anke Klippel-Giese Compounds and methods for the identification and/ or validation of a target
WO2004010900A1 (en) 2002-07-25 2004-02-05 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
WO2004089925A1 (en) * 2003-04-03 2004-10-21 Semafore Pharmaceuticals, Inc. Pi-3 kinase inhibitor prodrugs
ES2663248T3 (es) 2004-03-02 2018-04-11 The Johns Hopkins University Mutaciones del gen de PIK3CA en cánceres humanos

Also Published As

Publication number Publication date
EP2497836B1 (en) 2015-01-14
EP2896703B1 (en) 2017-10-25
CY1121975T1 (el) 2020-10-14
US20090208505A1 (en) 2009-08-20
CA2560696A1 (en) 2005-10-06
EP1730303A2 (en) 2006-12-13
AU2011200600B2 (en) 2012-02-23
ES2663248T3 (es) 2018-04-11
EP2497836A1 (en) 2012-09-12
US11549150B2 (en) 2023-01-10
US20180119231A1 (en) 2018-05-03
LT3296407T (lt) 2019-09-10
EP1730303A4 (en) 2009-09-09
JP2018023400A (ja) 2018-02-15
JP5336620B2 (ja) 2013-11-06
EP2896703A3 (en) 2015-10-21
ES2743125T3 (es) 2020-02-18
PT3296407T (pt) 2019-08-23
CA2560696C (en) 2019-06-25
ES2869167T8 (es) 2022-01-20
SI3296407T1 (sl) 2019-09-30
ES2869167T3 (es) 2021-10-25
AU2005227148B2 (en) 2010-11-11
JP2012183065A (ja) 2012-09-27
JP6395917B2 (ja) 2018-09-26
US10422006B2 (en) 2019-09-24
JP6694543B2 (ja) 2020-05-13
JP2022059046A (ja) 2022-04-12
US8026053B2 (en) 2011-09-27
EP3556866B1 (en) 2021-04-07
US10704105B2 (en) 2020-07-07
US20200248275A1 (en) 2020-08-06
PT1730303E (pt) 2013-10-31
JP6695381B2 (ja) 2020-05-20
JP2007530017A (ja) 2007-11-01
US20110319477A1 (en) 2011-12-29
US10787713B2 (en) 2020-09-29
JP7169315B2 (ja) 2022-11-10
EP3556866A1 (en) 2019-10-23
WO2005091849A3 (en) 2009-04-16
JP2016041078A (ja) 2016-03-31
WO2005091849A2 (en) 2005-10-06
JP7001735B2 (ja) 2022-02-10
AU2005227148A1 (en) 2005-10-06
AU2011200600A1 (en) 2011-03-10
JP7304987B2 (ja) 2023-07-07
JP2018153189A (ja) 2018-10-04
EP1730303B1 (en) 2013-07-31
PT3556866T (pt) 2021-04-30
SI1730303T1 (sl) 2013-12-31
JP2020092711A (ja) 2020-06-18
JP2013226141A (ja) 2013-11-07
EP3296407A1 (en) 2018-03-21
PL3296407T3 (pl) 2019-11-29
US20200024671A1 (en) 2020-01-23
JP5894110B2 (ja) 2016-03-23
JP6250017B2 (ja) 2017-12-20
EP2896703A2 (en) 2015-07-22
US20150079593A1 (en) 2015-03-19
JP2020028300A (ja) 2020-02-27
ES2537633T3 (es) 2015-06-10
DK3556866T3 (da) 2021-05-03
ES2437590T3 (es) 2014-01-13
HUE045690T2 (hu) 2020-01-28
PL1730303T3 (pl) 2014-04-30
JP2020115891A (ja) 2020-08-06
DK1730303T3 (da) 2013-11-04
EP3296407B1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
DK3296407T3 (da) Mutationer i PIK3CA-genet ved humane cancerformer
DE502004003234D1 (de) Gegen missbrauch gesicherte darreichungsform
DE502004004205D1 (de) Gegen missbrauch gesicherte darreichungsform
IL177847A0 (en) Use of lipid conjugates in the treatment of disease
DE602004010384D1 (de) Mutationen im menschlichen pcsk9 gen, die mit hypercholesterolämie assoziiert sind
NO20053534L (no) Mikrobryter
FR2872704B1 (fr) Pluritherapie contre le cancer
IL212214A0 (en) Use of lipid conjugates in the treatment of disease
ATA11422004A (de) Doppelwandige zarge
DE602005014972D1 (de) Teilchen
DE602005022667D1 (de) Haartrockner
ATA16512004A (de) Heizgerät
ATA3402004A (de) Kunstleder
IS8391A (is) Notkun á síramesíni við meðhöndlun á krabbameini
GB0409257D0 (en) Disease models and uses thereof
DE502004005704D1 (de) Dispersionen
RU44373U8 (ru) Электроводонагреватель
FI20045499A0 (fi) Järjestely oskillointilaitteessa
FI6317U1 (fi) Sähkökiuas
IL229982A0 (en) Use of fatty conjugates to treat diseases
IL229980A0 (en) Use of fatty conjugates to treat diseases
IL229981A0 (en) Use of fatty conjugates to treat diseases
UA9252S (uk) М`ясорубка
FIU20040056U0 (fi) Kannettava selkätuki
ES1058199Y (es) "barbacoa portatil".